Paradigm Biopharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Bankr. Admin/​Reorg

  • Financing Rounds
  • 8

  • Investments
  • 1

Paradigm Biopharmaceuticals General Information

Description

Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS. Its activities are conducted across Australia, the United States, Hong Kong, and Moldova through global clinical development programs and strategic research collaborations.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporation
Corporate Office
  • Level 15, 500 Collins Street
  • Melbourne, Victoria 3000
  • Australia
+61 (03)
Primary Industry
Drug Discovery
Former Stock Listing
PAR
Corporate Office
  • Level 15, 500 Collins Street
  • Melbourne, Victoria 3000
  • Australia
+61 (03)

Paradigm Biopharmaceuticals Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Paradigm Biopharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Paradigm Biopharmaceuticals‘s full profile, request access.

Request a free trial

Paradigm Biopharmaceuticals Patents

Paradigm Biopharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023902506-A0 Treatment of mucopolysaccharidosis Pending 08-Aug-2023
AU-2023901505-A0 Chemical pps modification Pending 16-May-2023
AU-2023901503-A0 Pps conjugates Pending 16-May-2023
AU-2022902567-A0 Treatment of psoriasis, psoriatic arthritis and dermatitis Pending 06-Sep-2022
AU-2023337133-A1 Treatment of psoriasis, psoriatic arthritis and dermatitis Pending 06-Sep-2022 A61K31/737
To view Paradigm Biopharmaceuticals’s complete patent history, request access »

Paradigm Biopharmaceuticals Acquisitions (1)

Paradigm Biopharmaceuticals’s most recent deal was a Merger/Acquisition with Proteobioactives for . The deal was made on 30-Sep-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Proteobioactives 30-Sep-2025 Merger/Acquisition Drug Discovery
To view Paradigm Biopharmaceuticals’s complete acquisitions history, request access »

Paradigm Biopharmaceuticals FAQs

  • When was Paradigm Biopharmaceuticals founded?

    Paradigm Biopharmaceuticals was founded in 2014.

  • Where is Paradigm Biopharmaceuticals headquartered?

    Paradigm Biopharmaceuticals is headquartered in Melbourne, Australia.

  • What industry is Paradigm Biopharmaceuticals in?

    Paradigm Biopharmaceuticals’s primary industry is Drug Discovery.

  • Is Paradigm Biopharmaceuticals a private or public company?

    Paradigm Biopharmaceuticals is a Private company.

  • What is Paradigm Biopharmaceuticals’s current revenue?

    The current revenue for Paradigm Biopharmaceuticals is .

  • How much funding has Paradigm Biopharmaceuticals raised over time?

    Paradigm Biopharmaceuticals has raised $103M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process